HomePharmacologyAntiplatelet

Antiplatelet

View Category

Acute coronary syndromes

Ticagrelor Monotherapy after 3 Months: Is the Current Strategy Worth Changing?

Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in...
solaci -
Learn More
Acute coronary syndromes

Abbreviated DAPT in ACS: The End of Clopidogrel Monotherapy?

Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to...
solaci -
Learn More
Acute coronary syndromes

Acute Coronary Syndrome: What Is Safer, Antiaggregant Monotherapy or De-Escalation?

For several years it has been shown that 12-month dual antiplatelet therapy (DAPT) is mandatory for patients...
solaci -
Learn More
Acute coronary syndromes

Cangrelor: Additional Research Findings Not Translating into Clinical Practice

The potent and fast endovenous platelet inhibition provided by Cangrelor reduces ischemic events early in the course...
solaci -
Learn More
Antiplatelet

Clnical Practice Dissociated from Study Outcomes: Bad News for Our Patients?

Differences in patient characteristics, changes in treatment algorithms, and advances in device technology, together or separately, might...
solaci -
Learn More
Acute coronary syndromes

TICO: Age Impacts the Effect of Antiplatelet Monotherapy

The higher the age, the greater the benefit of ticagrelor monotherapy vs. dual antiplatelet therapy (DAPT) in...
solaci -
Learn More
Antiplatelet

Post-PCI Ticagrelor Monotherapy in High-Risk Bleeding

In patients at high risk of bleeding undergoing coronary PCI and after completing 3-month DAPT with no...
solaci -
Learn More
Acute coronary syndromes

AHA 2021 | RAPID CABG: Safety of Early Surgical Intervention in Acute Coronary Syndrome

Suspending ticagrelor a couple of days before surgery was non-inferior to waiting 5-6 days in terms of...
solaci -
Learn More